Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

By Simone Fulda, Wolfgang Wick, Michael Weller, K. Debatin. Nature Medicine, 2002

751 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3a952c79c07137135de9ec30a117aa00786aeb39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Simone Fulda
2. K. Debatin
3. R. DePinho

In Molecular Biology

1. Simone Fulda
2. K. Debatin
3. D. Vučić
4. Alexandru Almasan
5. I. Kaplan
6. J. Wadia
7. S. Dowdy
8. R. Fischer

Citations in the corpus

• Targeting IAP proteins for therapeutic intervention in cancer (2012, background): “Even more importantly, a crucial study demonstrated the in vivo antitumour efficacy of SMAC peptides in combination with TRAIL in a malignant glioma xenograft mode”
• Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics (2009, positive): “Smac peptide associated to CPPs sensitizes cells to pro-apoptotic stimulus and a synergetic effect of Smac peptide and TNF-related apoptosis inducing ligand has been shown on intracranial glioblastoma xenografted mice (Fulda et al., 2002).”
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. (2003, background): “Smac/DIABLO agonists sensitize human acute leukemia Jurkat T cells for apoptosis induction by Apo2L/TRAIL or cancer chemotherapy agents [73] and induces regression of malignant glioma in vivo [74].”
• Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “…of effector caspase-9, caspase-3, and caspase-7 activity downstream from mitochondrial membrane disintegration, underscoring the importance of post-mitochondrial caspase activation for apoptosis propagation in glioma cell lines and its validity as a therapeutic target (Fulda et al. 2002).”
• Cationic TAT peptide transduction domain enters cells by macropinocytosis. (2005, background): “efficacy of treating mouse models of cancer by delivering anti-cancer peptides with PTDs [8–11].”
• Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy (2006, methodology): “Importantly, Smac peptides even enhanced the antitumor activity of TRAIL in vivo in an intracranial malignant glioma xenograft model (Fulda et al., 2002b).”
• A Comprehensive Model for the Cellular Uptake of Cationic Cell‐penetrating Peptides (2007, background): “Cytoplasmic delivery of the Smac peptide enhances apoptosis by promotion of caspase-3 activation (25).”